BMS-986231 in hepatic impairment

Phase 1, open-label trial of cimlanod in heart failure (HF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the concentration-time curve from time 0 extrapolated to infinity at 2 days, AUC from time 0 up to time T, where T is the last time point with concentrations above the lower limit of quantitation at 2 days and 1 more. Started May 2018; status: completed.